Analysed PROTARA THERAPEUTIC INC (TARA:NASDAQ) News Sources
Protara Therapeutics Highlights TARA-002 NMIBC Data, FDA Plans for Lymphatic Malformations at Oppenheimer Conf
02-03-2026
marketbeat.com
Protara Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update
10-03-2026
yahoo.com
Protara Therapeutics to Present Updated, Interim 12-Month Data from the Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the American Urological Association Annual Meeting
27-04-2026
yahoo.com
Protara Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update
13-05-2026
yahoo.com
Protara Therapeutics Announces Positive Updated 12-Month Data Demonstrating Durable Responses in the Fully Enrolled BCG-Naïve Cohort of the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in NMIBC
15-05-2026
yahoo.com
Protara Therapeutics to Host Virtual Investor Webinar to Discuss TARA-002 for Lymphatic Malformations on Tuesday, May 19, 2026
18-05-2026
yahoo.com
Protara Therapeutics to Present at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA
20-05-2026
yahoo.com
What is the current price of PROTARA THERAPEUTIC INC (TARA:NASDAQ)?
The current price of PROTARA THERAPEUTIC INC (TARA:NASDAQ) is $3.9.
PROTARA THERAPEUTIC INC (TARA:NASDAQ) absolute price change since previous trading day?
The absolute price change of PROTARA THERAPEUTIC INC (TARA:NASDAQ) since the previous trading day is $0.25.
PROTARA THERAPEUTIC INC (TARA:NASDAQ) percentage price change since previous trading day?
The percentage price change of PROTARA THERAPEUTIC INC (TARA:NASDAQ) since the previous trading day is 6.8493%.
What is the most recent average sentiment score for PROTARA THERAPEUTIC INC (TARA:NASDAQ)?
The most recent average sentiment score for PROTARA THERAPEUTIC INC (TARA:NASDAQ) is 74 out of 100.
What is the most recent average sentiment for PROTARA THERAPEUTIC INC (TARA:NASDAQ)?
The most recent sentiment for PROTARA THERAPEUTIC INC (TARA:NASDAQ) is .
SEC-8K** Filing Available For PROTARA THERAPEUTIC INC (TARA:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.